This week, we have nematodes in low Earth orbit, neckwear that reads your inner monologue, intestinal bacteria moonlighting as oncology consultants, an experimental aerosol that puts a 60-year-old-equivalent mouse brain back into its 30s, and the ongoing project of letting Big Tobacco hold a key card to the CDC.

RESEARCH

If you have ever tried to whisper "nuclear codes" in a noisy bar, the team at Korea's Pohang University of Science and Technology (POSTECH) has good news. Prof. Sung-Min Park and Dr. Sunguk Hong have built a silicone neckband that turns silently mouthed words into your own synthesized voice, no actual sound required. Their device, described in Cyborg and Bionic Systems, uses a flexible silicone collar dotted with reference markers, a tiny onboard camera, and an AI model that decodes the multiaxial strain map your throat makes when you form words.

Trained on the 26-word NATO phonetic alphabet (Alpha, Bravo, Charlie, and so on), the system hit 85.8% accuracy and reproduced the wearer's own voice after about 10 minutes of audio for personalization. It also held up at 90 dB of white noise (busy construction site) and during a gas-blowback rifle demonstration, where both noise and physical vibration tried to ruin the signal. The catch: when test subjects walked around, accuracy collapsed to 39.72%, so do not throw away your phone yet.

"We hope this technology will accelerate the day when patients with speech disorders can reclaim their voices," Park said, naming laryngectomy recovery, noisy industrial settings, and military scenarios as targets. Translation: the future of telling your spouse you love them without waking the baby is a 26-word vocabulary and a silicone neck hug.

RESEARCH

The Artemis II crew splashed down off San Diego at 8:07 p.m. EDT on April 10, 2026, completing humanity's first crewed lunar flyby in over 50 years. Less than 24 hours later, on April 11, their replacements lifted off: dozens of 1 mm Caenorhabditis elegans nematodes, riding NASA's Northrop Grumman CRS-24 mission on a Cygnus XL aboard a SpaceX Falcon 9.

The worms live in a Petri Pod: a 10 x 10 x 30 cm, 3 kg, self-contained biology lab with 12 experimental chambers (four imaged with fluorescent and white light), each holding its own mini-atmosphere, agar food, and trapped air for the worms to breathe in a vacuum. The project, called Fluorescent Deep Space Petri-Pods (FDSPP), is led by physiologist Tim Etheridge at the University of Exeter, engineered by Prof. Mark Sims at Space Park Leicester, integrated by Voyager Space Technologies, and funded by the UK Space Agency. After acclimating inside the ISS, the pod will be mounted on the station's exterior for up to 15 weeks of vacuum, microgravity, and cosmic radiation, with cameras streaming time-lapse worm telenovelas back to Earth.

"It might sound surprising, but these tiny worms could play a big role in the future of human spaceflight," said UK Space Minister Liz Lloyd. C. elegans shares enough biology with us that what kills them in deep space might also kill astronauts headed to the Moon, just faster and with better cameras.

RESEARCH

In a paper in Nature, Tariq A. Najar and senior author Dan R. Littman of NYU School of Medicine and Howard Hughes Medical Institute report something genuinely weird. The gut commensal segmented filamentous bacteria (SFB) live stuck to the small-intestine epithelium and train a stable population of Th17 cells against an SFB protein called SFB-3340. The Littman lab engineered B16-F10 melanoma cells (and MC-38 colon and LLC1 lung tumors) to express that same SFB-3340 fragment as a fake "tumor antigen," then implanted them in mice.

Anti-PD-1 alone barely touched the tumors. Anti-PD-1 in mice colonized with SFB whose tumors expressed the matching SFB antigen? Hammered. Using TCR lineage tracing, fate mapping, and MHCII tetramers, the team showed the SFB-trained gut Th17 cells migrate to the tumor and trans-differentiate into TH1-like "ex-Th17" cells that pump out IFN-γ and TNF, recruit and activate CD8+ cytotoxic T cells, and remodel the tumor microenvironment. Conditionally ablating SFB-induced IL-17A+ CD4+ T cells abolished the effect. A control commensal (Helicobacter hepaticus), which preferentially induces regulatory T cells, did nothing.

There are some important caveats, though: this is mouse data, the tumor antigen is engineered, and Littman discloses cofounding Vedanta Biosciences and ImmunAI, plus advisory roles at IMIDomics, Sonoma Biotherapeutics, and Evommune, and a board seat at Pfizer. Still, this is the cleanest causal demonstration to date that a single defined gut microbe, via molecular mimicry, can actually flip non-responders into responders.

RESEARCH

A study in the Journal of Extracellular Vesicles from Texas A&M University's Naresh K. Vashisht College of Medicine reports that two intranasal doses of a particular biological spray, given to 18-month-old C57BL/6J mice (humans in their late 50s to late 60s), restored memory and cognitive flexibility, with effects lasting months.

The active ingredient is hiPSC-NSC-EVs: extracellular vesicles harvested from neural stem cells derived from human induced pluripotent stem cells, loaded with cargo microRNAs. "MicroRNAs act like master regulators," said senior research scientist Dr. Madhu Leelavathi Narayana, the study's first author. "They help modulate and regulate many gene and signaling pathways in the brain." Squirted up the nose, the EVs hitch a ride along the olfactory nerves, sidestep the blood-brain barrier, and get gobbled up by hippocampal microglia.

Inside those microglia, the cargo suppresses two master inflammation switches: the NLRP3 inflammasome and the cGAS-STING pathway. The result was reduced astrocyte hypertrophy, fewer inflammatory microglial clusters, lower oxidative stress, and recharged neuronal mitochondria with broad transcriptomic shifts toward oxidative phosphorylation.

PI Ashok K. Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine, put it in patent-application English: "We are seeing the brain's own repair systems switch on, healing inflammation and restoring itself. As we develop and scale this therapy, a simple, two-dose nasal spray could one day replace invasive, risky procedures or maybe even months of medication." It is mouse data, no human trials, and the team is filing a patent. But if you know an 18-month-old mouse, this is huge for them.

In March 2026, Stephen C. Sayle was named CDC Deputy Director for Legislative Affairs. From 2017 to 2018, he was U.S. VP of Corporate Affairs at Fontem Ventures, the U.S. arm of British tobacco giant Imperial Brands, which markets blu e-cigarettes and Zone oral nicotine pouches. STAT News broke the story on April 22, 2026.

For you (near) history nerds: in January 2018, CDC Director Brenda Fitzgerald resigned within roughly 24 hours of Politico revealing she had bought $1,001 to $15,000 of Japan Tobacco stock about a month after taking the job, then toured the CDC Tobacco Laboratory the very next day. That was the public health norm. We have since updated it.

In an editorial in Tobacco Control, Dr. Timothy McAfee, who ran the CDC's Office on Smoking and Health from 2010 to 2017, called the appointment "unprecedented" and said it was "opening a door that has been closed for decades, and letting the fox into the henhouse with open arms." HHS spokesperson Andrew Nixon defended the hire, noting Sayle "brings more than 25 years of experience working at senior levels of the federal government and will be a valuable asset at the CDC to ensure effective coordination with Congress." Sayle reportedly holds no tobacco stock. He was previously CEO of Dow Lohnes Government Strategies, which lobbied for Chevron, then served as a House Science Committee staff director, and was named one of The Hill's Top Hired Guns in 2010, 2011, and 2012.

Still, context matters: on April 1, 2025, HHS effectively shuttered the CDC's Office on Smoking and Health, dismissing roughly 120 full-time staff and gutting the National Youth Tobacco Survey and the long-running Tips From Former Smokers campaign. Former CDC Director Tom Frieden called it a "gift to Big Tobacco," telling NBC News, "The only winner here is the tobacco industry and cancer cells." Meanwhile, Sayle's old employer, Fontem U.S., is currently suing HHS Secretary RFK Jr., FDA Commissioner Marty Makary, and the FDA over the stalled premarket authorization for Zone nicotine pouches. The federal officials being sued by his former employer are now, in a federal org-chart sense, his colleagues.

That is our week this time: silent speech is almost solved (if you stay seated), worms are doing the long-haul deep-space work humans can't yet afford, gut bacteria might be the missing ingredient in cancer immunotherapy (in mice with engineered tumors, calm down), nasal sprays might rewind brain aging (in mice, also calm down), and the CDC is once again deciding whether the firewall between public health and the products that kill 480,000 Americans a year is load-bearing.

We will continue covering the science with the appropriate mix of awe, due diligence, and a healthy dose of humorous skepticism. If a paper says "in mice," we will say "in mice." If a press release uses the word "revolutionary," we will check whether it actually overturns anything or just our trust in it. And if a tobacco lobbyist gets a federal office, we will tell you which lawsuits are on his old employer's docket.

Forward this to a friend who still uses a corded landline or the one who pre-ordered the Apple Vision Pro 3.

Keep questioning everything (especially anything you can't whisper to your neckband),

Prateek & Jere

P.S. If you are reading this from a noisy bar while silently mouthing the words to your seatmate, please tell us the accuracy rate. For science.